9th Annual Biomarkers Congress

Cell Biology: GlaxoSmithKline

Total Score People Score Events Score
26 24 22
Date Event Presentation Speakers
April 6, 2013 AACR Annual Meetings From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Targeting Epigenetics: An Epicenter of Oncology Drug Discovery? Chairperson: Ho Man Chan, Novartis Institutes for BioMedical Research, Cambridge, MA Dashyant Dhanak
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Oncology Drug Discovery and Development: Combination Therapies Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC Tona M Gilmer, Axel Hoos
February 20, 2012 Advances and Progress in Drug Design Molecular obesity, potency and other addictions in medicinal chemistry Mike Hann,
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics BRAF and MEK inhibition in melanoma Tona M Gilmer
March 7, 2011 Imaging in Cancer Drug Development The role of PET in drug development Jan Passchier
February 26, 2011 Immunity in the Respiratory Tract: Challenges of the Lung Environment (X6) Immunotherapy: Helping the Host | TLR4 Agonists Facilitate “Rapid Acting Vaccine” Against the Respiratory Tract Pathogen, Influenza A Jory R. Baldridge
February 26, 2011 Mucosal Biology: A Fine Balance between Tolerance and Immunity (X5) Immunity in Respiratory Tract (X6) | TLR4 Agonists Facilitate “Rapid Acting Vaccine” Against the Respiratory Tract Pathogen, Influenza A Jory R. Baldridge
February 12, 2011 Cancer Control by Tumor Suppressors and Immune Effectors (J8) Cancer Vaccines: Prophylaxy or Therapy | Development of the MAGE-A3 ASCI: From Tumor Specificity to Predictive Biomarkers Vincent G Brichard
August 10, 2010 The International Quantitative Imaging Cytometry Centers of Excellence Provide a Forum for Educational and Training Programs in Quantitative Imaging Cytometry, with a Specific Focus on Solid-Phase Laser Scanning Imaging Cytometry Workshop II | Quantitative Assessment of Pancreatic Islets David Krull
May 10, 2010 The New Science of Ageing Drug discovery for a broadspectrum, preventative medicine for ageing P Vallance
September 23, 2009 TRACK 4: Bridging Silos in Biomarker Development : Third Annual Biomarker Data Analysis An Effective Framework for Omic Data Analysis Jie J. Cheng
August 26, 2009 Affinity Tag Protein Purification Producing Biologically Active Chemokines Quinn Lu, Ph.D., Biological Reagents and Assay Development Quinn Lu
June 22, 2009 Collaborative Innovation in Biomedicine Successes and Renewal of the Dundee Signaling Consortium Malcolm M. Skingle
The Innovative Medicines Initiative: Driving a New Paradigm in Pre-Competitive Research Jackie Hunter
The Future of Pre-Competitive Consortia – A Best Practices Panel Discussion Jackie Hunter
June 9, 2009 Cell and Tissue-Based Assays for HTS Novel Assays and New Technologies Kalpana Patel
Table Six: Novel Assays, New Technologies and their Applications Kalpana Patel
February 23, 2009 Advances and Progress in Drug Design VIII STRUCTURE BASED DRUG DESIGN WITH EMPHASIS ON GPCR MODELLING Frank Blaney
December 2, 2008 2nd Annual Lead Discovery Summit 2008:--Primary & Secondary Screening Comparison of results obtained with different cell types: Should we look to use more disease relevant cells at an earlier stage? Gareth J. Wayne,
Biological fingerprints: Acceleration of hit identification and decision making in drug discovery Wolfgang Jarolimek,
March 25, 2008 Preclinical Development Advances in Liver Toxicity Testing: What’s on the Horizon? Holly L Jordan
March 25, 2008 RNAi, MicroRNA, and Non-Coding RNA MicroRNAs and Their Targets (Plants and Invertebrates) Eric C Lai
November 7, 2007 Stem Cells and Primary Cells in Drug Discovery Welcome Remarks Robert Ames
October 17, 2007 Exploring Next Generation Sequencing: Applications and Case Studies (Oct 17-18) Deep Sequencing (12:00-15:30) E. Randall Lanier
Deep Sequencing: Deep Sequence of HIV RT Regions in Search of Drug Resistance Mutations in Patients Undergoing RT Inhibitor Treatment (14:05-14:35) E. Randall Lanier
October 11, 2007 Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12) SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30) Dana E. Vanderwall
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Biological Mechanism of Action, and Characterization of Profiles across the Progression Path (14:05-14:35) Dana E. Vanderwall
September 24, 2007 High-Content Analysis Europe: High content Cellular Assays for compound screening and Pahtway Analysis (Sep 24-26) HCA for Mechanism-of-Action Studies: Use of the BD Pathway in CNS Drug Discovery to Determine Mechanisms of Compound Action in Primary Neuronal Cultures (16:00-16:30) Claire Scott
HCA for Mechanism-of-Action Studies (16:00-18:00) Claire Scott
September 19, 2007 Baculovirus Technology (Sep 19-20) Baculovirus: The Big Picture (08:30-10:35) Michel Deschuyteneer
Baculovirus - The Big Picture: FEATURED SPEAKER - Quality Assessment of GSK’s Cervical Cancer Candidate Vaccine Manufactured with the Baculovirus Expression Vector System (BEVS) (09:20-10:00) Michel Deschuyteneer
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.